Next-Generation Cancer Nanovaccines: Reprogramming the Tumor Microenvironment from Rational Design Toward Clinical Translation.

Authors

Sarvin Tabibzadeh, Fansu Meng, Vahid Asghariazar, Elham Safarzadeh, Ali Esmaeili, Timo L M Ten Hagen, Leila Farhoudi, Yu Cai

Published in

International journal of nanomedicine. Volume 21. Pages 645776. Epub Nov 03, 2026.

Abstract

Cancer vaccines have emerged as a promising immunotherapeutic strategy for inducing durable and tumour-specific immune responses; however, their clinical efficacy remains limited by poor antigen immunogenicity, inefficient delivery, tumor heterogeneity, and the highly immunosuppressive tumor microenvironment (TME). Recent advances in nanotechnology have expanded opportunities for the rational engineering of multifunctional nanoparticle (NP) platforms that can protect therapeutic cargo, enhance antigen presentation and lymphatic transport, co-deliver immunostimulatory adjuvants, and potentially improve immune modulation while reducing systemic exposure. This narrative review provides an overview of next-generation cancer nanovaccines, including lipid-, polymer-, peptide-, inorganic-, biomimetic-, theranostic, in situ-, and stimuli-responsive platforms, with emphasis on their physicochemical design principles, mechanisms of immune activation, and interactions with the TME. Particular attention is given to strategies targeting tumor -associated macrophages, myeloid-derived suppressor cells, regulatory T cells, cancer-associated fibroblasts, and tumor cells to support dendritic-cell maturation, cytotoxic T-cell activation, and anti-tumor immunity. Emerging personalized approaches, including neoantigen- and autologous cell-based nanovaccines, mRNA vaccine platforms, and combinations with immune checkpoint inhibitors, are also discussed. In addition, we examine the growing role of artificial intelligence, machine learning, and computational immunology in neoantigen prioritization, nanoparticle formulation optimization, immunogenicity prediction, and patient-specific vaccine design. Despite encouraging preclinical findings, most cancer nanovaccine platforms remain at the preclinical or early clinical stage, and translation is limited by tumor heterogeneity, variable immune responses, long-term safety and biodistribution concerns, manufacturing reproducibility, scale-up, and regulatory requirements. Overall, the integration of nanotechnology, immunology, precision medicine, and AI offers considerable potential to advance personalized cancer vaccination, but broader clinical validation and standardized manufacturing and evaluation frameworks are required before these platforms can achieve routine clinical application.

PMID:
42999844
Bibliographic data and abstract were imported from PubMed on 08 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.